Pfizer releases vaccine data for 5-11 age group, affirms safety and efficacy
Pfizer today the first data evaluating a COVID-19 vaccine鈥檚 safety and effectiveness for children between the ages of 5 and 11. The data, culled from a phase 2/3 trial, indicates that two, 10-microgram doses of Pfizer鈥檚 mRNA vaccine, administered 21 days apart, resulted in a strong immune response against SARS-CoV-2. Pfizer said the data would be included in a 鈥渘ear-term鈥 application to the Food and Drug Administration for emergency use authorization in the 5-11 age group. The drug maker also indicated that it would soon have sufficient trial data for children under 5 for submission to FDA.
Related News Articles
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.鈥檚 nomination for secretary of the Department of Health and Human Services. A鈥
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the鈥
Headline
CDC recommends two doses of COVID-19 vaccine for older individuals, lowers pneumococcal vaccine age聽
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to鈥
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their鈥
Chairperson's File
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers鈥
Headline
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a鈥